Updated projection of US durable cell and gene therapies product-indication approvals based on December 2019 development pipeline

Eric NormanFoCUS, Research Briefs

Ongoing pipeline modeling by the MIT NEWDIGS FoCUS team projects 10X growth from July 2020 levels, but with large uncertainties. Download FoCUS Research Brief 2020F207v51Share the research

Tracking the CAR-T revolution: Analysis of clinical trials of CAR-T and TCR therapies for the treatment of cancer

Eric NormanFoCUS, Whitepapers

Chimeric antigen receptor and T-cell receptor (CAR-T/TCR) cellular immunotherapies have shown remarkable success in the treatment of some refractory B-cell malignancies, with potential to provide durable clinical response for other … Read More

FoCUS Monthly Recap: June 2020

Eric NormanFoCUS, News

WHITE PAPER Tracking the CAR-T revolution: Analysis of clinical trials of CAR-T and TCR therapies for the treatment of cancerWe look at all available FDA CAR-T/TCR clinical trials for the … Read More

LEAPS Monthly Recap: June 2020

Eric NormanLEAPS, News

JUNE VIRTUAL DESIGN LAB RECAP Adaptive Reimbursement: Innovating for Patient Access & Better Outcomes for All Adaptive Reimbursement was explored at the NEWDIGS LEAPS Design Lab by a panel representing … Read More

LEAPS Monthly Recap: may 2020

Eric NormanLEAPS, News

LEAPS JUNE VIRTUAL DESIGN LABTwo exciting new confirmed developments New Session: Real World Platform Strategies Through the Lens of a Pandemic The ongoing pandemic has generated a flurry of innovation as … Read More

FoCUS Monthly Recap: may 2020

Eric NormanFoCUS, News

NEW RESOURCES Paying for Cures Toolkit updated with new material for patients and developers Version 2 of the free online resource adds new sections for patients and developers, and provides … Read More